文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

2000-2022年血液系统恶性肿瘤患者因脓毒症入住ICU的死亡率:一项两国队列研究

Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study.
PubMed 文献 · Crit Care · 2024-05-06
一句话结论2000至2021年,因脓毒症入住ICU的血液系统恶性肿瘤患者院内死亡率从55.6%降至23.1%,调整后死亡比值年降幅大于无血液系统恶性肿瘤者(OR 0.954 vs 0.968,p<0.001),但绝对死亡率仍更高。

该研究为回顾性队列研究,纳入2000年1月至2022年12月澳大利亚和新西兰216个ICU中282,627例以脓毒症为主要入ICU诊断的患者,其中17,313例合并血液系统恶性肿瘤。合并血液系统恶性肿瘤者院内脓毒症死亡率从2000年的55.6%(95%CI 46.5-64.6%)降至2021年的23.1%(95%CI 20.8-25.5%);无血液系统恶性肿瘤者从33.1%(95%CI 31.3-35.1%)降至14.4%(95%CI 13.8-14.8%)。调整年龄、SOFA评分和合并症等死亡预测因素后,死亡比值年降幅在血液系统恶性肿瘤患者中更大(OR 0.954,95%CI 0.947-0.961 vs OR 0.968,95%CI 0.966-0.971,p<0.001)。但血液系统恶性肿瘤患者的院内死亡绝对风险仍高于无血液系统恶性肿瘤者。

要点

  • 合并血液系统恶性肿瘤的脓毒症患者院内死亡率从2000年55.6%(95%CI 46.5-64.6%)降至2021年23.1%(95%CI 20.8-25.5%)。
  • 无血液系统恶性肿瘤者院内死亡率从33.1%(95%CI 31.3-35.1%)降至14.4%(95%CI 13.8-14.8%)。
  • 调整年龄、SOFA评分和合并症后,血液系统恶性肿瘤患者死亡比值年降幅更大(OR 0.954,95%CI 0.947-0.961 vs OR 0.968,95%CI 0.966-0.971,p<0.001)。
  • 尽管降幅更大,血液系统恶性肿瘤患者的院内死亡绝对风险仍高于无血液系统恶性肿瘤者。
  • 高龄、较高SOFA评分、存在合并症及机械通气与死亡率增加相关;白细胞计数<1.0×10^9/L与死亡率增加无关(p=0.60)。

适用人群与场景

  • 2000年1月至2022年12月入住澳大利亚或新西兰216个ICU、以脓毒症为主要入ICU诊断的成人患者,共282,627例,其中17,313例合并血液系统恶性肿瘤。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量282,627例(其中血液系统恶性肿瘤17,313例);216个ICU;地点为澳大利亚和新西兰;时间2000年1月至2022年12月。
  • 合并血液系统恶性肿瘤者院内脓毒症死亡率从2000年55.6%(95%CI 46.5-64.6%)降至2021年23.1%(95%CI 20.8-25.5%)。
  • 无血液系统恶性肿瘤者院内死亡率从2000年33.1%(95%CI 31.3-35.1%)降至2021年14.4%(95%CI 13.8-14.8%)。
  • 调整年龄、SOFA评分和合并症等死亡预测因素后,死亡比值年降幅在血液系统恶性肿瘤患者中更大(OR 0.954,95%CI 0.947-0.961 vs OR 0.968,95%CI 0.966-0.971,p<0.001)。
  • 高龄、较高SOFA评分、存在合并症及机械通气与死亡率增加相关。
  • 白细胞减少(白细胞计数<1.0×10^9 cells/L)与血液系统恶性肿瘤患者死亡率增加无关(p=0.60)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:因脓毒症入住ICU的血液系统恶性肿瘤患者死亡率已改善,但仍高于无血液系统恶性肿瘤者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis occurs in 12-27% of patients with haematological malignancy within a year of diagnosis. Sepsis mortality has improved in non-cancer patients in the last two decades, but longitudinal trends in patients with haematological malignancy are not well characterised. We aimed to compare outcomes, including temporal changes, in patients with and without a haematological malignancy admitted to ICU with a primary diagnosis of sepsis in Australia and New Zealand over the past two decades.

METHODS: We performed a retrospective cohort study of 282,627 patients with a primary intensive care unit (ICU) admission diagnosis of sepsis including 17,313 patients with haematological malignancy, admitted to 216 intensive care units (ICUs) in Australia or New Zealand between January 2000 and December 2022. Annual crude and adjusted in-hospital mortality were reported. Risk factors for in-hospital mortality were determined using a mixed methods logistic regression model and were used to calculate annual changes in mortality.

RESULTS: In-hospital sepsis mortality decreased in patients with haematological malignancy, from 55.6% (95% CI 46.5-64.6%) in 2000 to 23.1% (95% CI 20.8-25.5%) in 2021. In patients without haematological malignancy mortality decreased from 33.1% (95% CI 31.3-35.1%) to 14.4% (95% CI 13.8-14.8%). This decrease remained significant after adjusting for mortality predictors including age, SOFA score and comorbidities, as estimated by adjusted annual odds of in-hospital death. The reduction in odds of death was of greater magnitude in patients with haematological malignancy than those without (OR 0.954, 95% CI 0.947-0.961 vs. OR 0.968, 95% CI 0.966-0.971, p < 0.001). However, absolute risk of in-hospital mortality remained higher in patients with haematological malignancy. Older age, higher SOFA score, presence of comorbidities, and mechanical ventilation were associated with increased mortality. Leukopenia (white cell count < 1.0 × 109 cells/L) was not associated with increased mortality in patients with haematological malignancy (p = 0.60).

CONCLUSIONS: Sepsis mortality has improved in patients with haematological malignancy admitted to ICU. However, mortality remains higher in patients with haematological malignancy than those without.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. MacPhail A, Dendle C, Slavin M, et al. Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study. Crit Care. 2024. PMID: 38711155. doi:10.1186/s13054-024-04932-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。